SecProbe.io

CORRESP
 1
 filename1.htm

 Indaptus
Therapeutics, Inc.

 3
Columbus Circle

 15th
Floor

 New
York, NY 10019

 August
19, 2025

 VIA
EDGAR

 Securities
and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E.

 Washington,
DC 20549

 RE:
 Indaptus
 Therapeutics, Inc.
 (CIK
 0001857044)

 Registration
 Statement No. 333-289576 on Form S-3 (the " Registration Statement ")

 Ladies
and Gentlemen:

 Indaptus
Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on August 20, 2025, at 4:00
p.m., Eastern Time, or as soon thereafter as is practicable.

 The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Gary Emmanuel at 212-801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

 Very
truly yours,

 INDAPTUS
 THERAPEUTICS, INC.

 By:
 /s/
 Nir Sassi

 Nir
 Sassi

 Chief
 Financial Officer

CORRESP
 1
 filename1.htm

 Indaptus
Therapeutics, Inc.

 3
Columbus Circle

 15th
Floor

 New
York, NY 10019

 August
19, 2025

 VIA
EDGAR

 Securities
and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E.

 Washington,
DC 20549

 RE:
 Indaptus
 Therapeutics, Inc.
 (CIK
 0001857044)

 Registration
 Statement No. 333-289573 on Form S-3 (the " Registration Statement ")

 Ladies
and Gentlemen:

 Indaptus
Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on August 20, 2025, at 4:00
p.m., Eastern Time, or as soon thereafter as is practicable.

 The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Gary Emmanuel at 212-801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

 Very
 truly yours,

 INDAPTUS
 THERAPEUTICS, INC.

 By:
 /s/
 Nir Sassi

 Nir
 Sassi

 Chief
 Financial Officer

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 18, 2025

Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019

 Re: Indaptus Therapeutics, Inc.
 Registration Statement on Form S-3
 Filed August 13, 2025
 File No. 333-289576
Dear Jeffrey Meckler:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gary Emmanuel, Esq.
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 18, 2025

Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019

 Re: Indaptus Therapeutics, Inc.
 Registration Statement on Form S-3
 Filed August 13, 2025
 File No. 333-289573
Dear Jeffrey Meckler:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Gary Emmanuel, Esq.
</TEXT>
</DOCUMENT>

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle

15th
Floor

New
York, NY 10019

February
13, 2025

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Indaptus
    Therapeutics, Inc.

    (CIK
    0001857044)

    Registration
    Statement No. 333-284863 on Form S-1 (the “Registration Statement”)

Ladies
and Gentlemen:

Indaptus
Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may
become effective on February 13, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Gary Emmanuel at 212-801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

    Very
    truly yours,

    INDAPTUS
    THERAPEUTICS, INC.

    By:
    /s/
    Nir Sassi

    Nir Sassi

    Chief
    Financial Officer

February 12, 2025
Jeffrey A. Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed February 12, 2025
File No. 333-284863
Dear Jeffrey A. Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle

15th
Floor

New
York, NY 10019

February
11, 2025

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Indaptus
    Therapeutics, Inc. (CIK 0001857044)

    Registration
    Statement No. 333-284707 on Form S-3 (the “Registration Statement”)

Ladies
and Gentlemen:

Indaptus
Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may
become effective on February 11, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, LLP, by calling Gary Emmanuel at +1-212-801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

    Very
    truly yours,

    Indaptus
    Therapeutics, Inc.

    By:
    /s/
    Nir Sassi

    Nir
    Sassi

    Chief
    Financial Officer

February 7, 2025
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle, 15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-3
Filed February 5, 2025
File No. 333-284707
Dear Jeffrey Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.

December 30, 2024
Jeffrey A. Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle, 15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 23, 2024
File No. 333-284026
Dear Jeffrey A. Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle

15th
Floor

New
York, NY 10019

December
30, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Indaptus
    Therapeutics, Inc. (CIK 0001857044)

    Registration
    Statement No. 333-284026 on Form S-1 (the “Registration Statement”)

Ladies
and Gentlemen:

Indaptus
Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration
Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may
become effective on December 31, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, LLP, by calling Gary Emmanuel at +1-212-801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

    Very
    truly yours,

    Indaptus
    Therapeutics, Inc.

    By:
    /s/
    Nir Sassi

    Nir
    Sassi

    Chief
    Financial Officer

CORRESP
1
filename1.htm

September
18, 2024

Via
EDGAR Transmission

United
States Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Lauren Hamill

    Re:
    Indaptus
    Therapeutics, Inc.

    Registration
    Statement on Form S-1

    Originally
    Filed September 12, 2024

    Registration
    No. 333-282069

Ladies
and Gentlemen:

In
accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby
request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on Friday,
September 20, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Indaptus Therapeutics,
Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Elisabeth M. Martin
of Latham & Watkins LLP at (617) 948-6018 to provide notice of effectiveness, or if you have any other questions or concerns regarding
this matter.

    Sincerely
    yours,

    Indaptus
    Therapeutics, Inc.

    By:
    /s/
    Nir Sassi

    Nir
    Sassi

    Chief
    Financial Officer

    cc:
    Peter
    N. Handrinos, Latham & Watkins LLP

September 17, 2024
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 12, 2024
File No. 333-282069
Dear Jeffrey Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Lisa Martin

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle

15th
Floor

New
York, New York 10019

December
30, 2022

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Indaptus
    Therapeutics, Inc.

    Registration
    Statement on Form S-1

    File No. 333-269000

VIA
EDGAR

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Indaptus Therapeutics, Inc. (the “Registrant”) hereby respectfully
requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-269000) of the Registrant (the “Registration
Statement”) be accelerated so that the Company’s Registration Statement will be declared effective at 4.30 p.m., Eastern
Time, on December 30, 2022, or as soon thereafter as may be practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Eyal Peled at (212) 801 9210. The Company hereby authorizes Mr. Peled to orally modify or withdraw
this request for acceleration.

    Very
    truly yours,

    INDAPTUS
    THERAPEUTICS, INC.

    By:
    /s/
    Nir Sassi

    Name:
    Nir
    Sassi

    Title:
    Chief
    Financial Officer

    cc:
    Gary
    Emmanuel (Greenberg Traurig, P.A.)

United States securities and exchange commission logo
December 29, 2022
Jeffrey Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 23, 2022
File No. 333-269000
Dear Jeffrey Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Gary M. Emmanuel, Esq.

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle

15th
Floor

New
York, New York 10019

September
7, 2022

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Indaptus
    Therapeutics, Inc.

    Registration
    Statement on Form S-3

    File
    No. 333-267236

VIA
EDGAR

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Indaptus Therapeutics, Inc. (the “Registrant”) hereby respectfully
requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-267236) of the Registrant (the “Registration
Statement”) be accelerated so that the Company’s Registration Statement will be declared effective at 9.30 a.m., Eastern
Time, on September 9, 2022, or as soon thereafter as may be practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify
or withdraw this request for acceleration.

    Very
    truly yours,

    INDAPTUS
    THERAPEUTICS, INC.

    By:
    /s/
    Nir Sassi

    Name:
    Nir
    Sassi

    Title:
    Chief
    Financial Officer

    cc:
    Gary
    Emmanuel (McDermott Will & Emery LLP)

United States securities and exchange commission logo
September 7, 2022
Nir Sassi
Chief Financial Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 1, 2022
File No. 333-267236
Dear Mr. Sassi:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Ansart at 202-551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Gary Emmanuel

CORRESP
1
filename1.htm

Indaptus
Therapeutics, Inc.

3
Columbus Circle, 15th Floor

New
York, NY 10019

September
28, 2021

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Indaptus
    Therapeutics, Inc.

    Registration
    Statement on Form S-1

    File
    No. 333-259771

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Indaptus Therapeutics, Inc. (the “Registrant”) hereby respectfully
requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-259771) of the Registrant (the “Registration
Statement”) be accelerated so that it will be declared effective at 1:00 p.m., Eastern Time, on September 29, 2021 or as soon thereafter
as may be practicable.

The
Registrant hereby acknowledges that:

 ● should
                                            the Securities and Exchange Commission (the “Commission”) or the staff, acting
                                            pursuant to delegated authority, declare the Registration Statement effective, it does not
                                            foreclose the Commission from taking any action with respect to the Registration Statement;

 ● the
                                            action of the Commission or the staff, acting pursuant to delegated authority, in declaring
                                            the Registration Statement effective, does not relieve the Registrant from its full responsibility
                                            for the adequacy and accuracy of the disclosure in the filing; and

 ● the
                                            Registrant may not assert staff comments and the declaration of effectiveness as a defense
                                            in any proceeding initiated by the Commission or any person under the federal securities
                                            laws of the United States.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
McDermott Will & Emery LLP, by calling Ze’-ev Eiger at (212) 547-5470. The Registrant hereby authorizes Mr. Eiger to orally
modify or withdraw this request for acceleration.

    Very
    truly yours,

    INDAPTUS
    THERAPEUTICS, INC.

    By:
    /s/
    Jeffrey A. Meckler

    Name:
    Jeffrey
    A. Meckler

    Title:
    Chief
    Executive Officer

United States securities and exchange commission logo
September 27, 2021
Jeffrey A. Meckler
Chief Executive Officer
Indaptus Therapeutics, Inc.
3 Columbus Circle
15th Floor
New York, NY 10019
Re:Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 24, 2021
File No. 333-259771
Dear Mr. Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Gary Emmanuel, Esq.

CORRESP
1
filename1.htm

Intec
Parent, Inc.

12
Hartom Street

Har
Hotzvim, Jerusalem 9777512

Israel

    May
    13, 2021

Securities
and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Intec
    Parent, Inc.

    Registration
        Statement on Form S-4

        File
No. 333-255389

VIA
EDGAR

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Intec Parent, Inc. (the “Registrant”) hereby respectfully
requests that the effectiveness of the Registration Statement on Form S-4 (File No. 333-255389) of the Registrant (the “Registration
Statement”) be accelerated so that it will be declared effective at 12:00 p.m., Eastern Time, on May 14, 2021 or as
soon thereafter as may be practicable.

The
Registrant hereby acknowledges that:

    ●
    should
    the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority,
    declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to
    the Registration Statement;

    ●
    the
    action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective,
    does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing;
    and

    ●
    the
    Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
    the Commission or any person under the federal securities laws of the United States.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to
our counsel, McDermott Will & Emery LLP, by calling Ze’-ev Eiger at (571) 213-6976. The Registrant hereby authorizes
Mr. Eiger to orally modify or withdraw this request for acceleration.

    Very truly yours,

    INTEC PARENT, INC.

    By:
    /s/
    Jeffrey Meckler

    Name:
     Jeffrey Meckler

    Title:
     Chief Executive Officer

United States securities and exchange commission logo
April 22, 2021
Jeffrey Meckler
Chief Executive Officer
Intec Parent Inc.
12 Hartom Street
Har Hotzvim, Jerusalem 9777512
Re:Intec Parent Inc.
Registration Statement on Form S-4
Filed April 20, 2021
File No. 333-255389
Dear Mr. Meckler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Gary Emmanuel - McDermott Will & Emery LLP